- ►annals.org A Saven, LD Piro - Annals of internal medicine, 1994 - Am Coll Physicians Data Synthesis: 2-Chlorodeoxyadenosine is unique compared with traditional antimetabolite
drugs in that it is equally active against dividing and resting lymphocytes, which may be especially
important in indolent lymphoid malignancies, such as chronic lymphocytic leukemia, ... Cited by 60 - Related articles - BL Direct - All 3 versions
T Hickish, P Serafinowski, D Cunningham, A … - British journal of …, 1993 - pubmedcentral.nih.gov 2'-Chlorodeoxyadenosine (2CDA) is a purine analogue selectively active against both resting
and dividing lymphoid cells. Twenty-one patients with a variety of previously treated lymphoid
malignancies received a total of 41 courses of 2CDA (0.1-0.15 mg/kg/day over 7 days ... Cited by 46 - Related articles - BL Direct - All 3 versions
[CITATION] 2. 2-Chlorodeoxyadenosine treatment of lymphoma
A Saven, LD Piro - Advances in lymphoma research, 1996 - Kluwer Academic Pub Related articles
[CITATION] Restoration of lymphocyte subsets following 2-chlorodeoxyadenosine remission …
AK Morris, B PharmD, JM Kolesar, JG Kuhn, F … - Journal of Oncology … - opp.sagepub.com Purpose. The pharmacology, pharmacokinetics, clin- issues, and cost issues of the commercially
available ... Data Sources. We searched the literature using tostatin display significant activity
in hairy cell leuke- ... MEDLINE from 1986 to 1997. Relevant articles cited mia; cladribine ... Related articles
- ►nih.gov [PDF] CJ Carrera, C Terai, M Lotz, JG Curd, LD … - Journal of Clinical …, 1990 - pubmedcentral.nih.gov Lymphoid cells were thought to be uniquely susceptible to excess 2'-deoxyadenosine
(dAdo), when exposed to inhibitors of adenosine deaminase (ADA). However, we now find that
human monocytes are as sensitive as lymphocytes to dAdo or to the ADA-resistant ... Cited by 90 - Related articles - All 5 versions
HJ Guchelaar, DJ Richel, MR Schaafsma - Annals of Hematology, 1994 - Springer Summary Cladribine (2-chlorodeoxyadenosine, 2- CdA) is a new antineoplastic drug which exerts
its anti- lymphoproliferative activity by its resistance to the en- zyme adenosine deaminase. Cladribine
is mostly ad- ministered as a 7-day continuous infusion and in a dose of 0.1 mg/kg/day. ... Cited by 18 - Related articles - BL Direct - All 3 versions
DA Carson, DB Wasson, E Beutler - Proceedings of the …, 1984 - National Acad Sciences Proc. Nati. Acad. Sci. USA Vol. 81, pp. 2232-2236, April 1984 Medical Sciences ... DENNIS
A. CARSON, D. BRUCE WASSON, AND ERNEST BEUTLER ... Department of Basic and Clinical
Research, Scripps Clinic and Research Foundation, 10666 North Torrey Pines Road, La Cited by 113 - Related articles - All 9 versions
- ►ascopubs.org [PDF] J Liliemark, F Albertioni, M Hassan, G … - Journal of Clinical …, 1992 - jco.ascopubs.org Purpose: The antimetabolite 2-chloro-2'-deoxyade- nosine (CdA) is a promising alternative to
alkylating agents for the treatment of lymphoproliferative disor- ders. Its use, however, is hampered
by the need for intravenous (IV) administration. The aim of the present study was to ... Cited by 85 - Related articles - BL Direct - All 6 versions
A Saven, L Piro - The New England journal of medicine, 1994 - nejm.highwire.org Hairy-cell Leukemia, or leukemic reticuloendotheliosis, is an uncommon chronic lymphoproliferative
disorder first described by Bouroncle et al. in 1958 1 . Its defining features are mononuclear cells
with prominent cytoplasmic projections (Figure 1) that retain acid phosphatase stain when ... Cited by 88 - Related articles - BL Direct - All 5 versions
